Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.
Therapeutic Effects of Allogene MSCs Transplantation in Patients With Chronic Liver Diseases Through Peripheral Vein.
1 other identifier
observational
60
1 country
1
Brief Summary
Allogene MSCs transplantation will be performed in patients with chronic liver diseases through peripheral vein and therapeutic effects including short-term effects and long-term follow-up will be compared and investigated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2010
CompletedFirst Submitted
Initial submission to the registry
December 7, 2010
CompletedFirst Posted
Study publicly available on registry
December 8, 2010
CompletedDecember 8, 2010
October 1, 2010
December 7, 2010
December 7, 2010
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Short-term therapeutic effects at 1-8 weeks after Allogene MSCs transplantation through peripheral vein.
1-8 weeks after transplantation
Secondary Outcomes (1)
Long-term follow-up of Allogene MSCs transplantation through peripheral vein.
3-60 months
Study Arms (2)
Allogene MSCs transplantation
Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
control
only medical treatments were performed in patients with chronic liver diseases.
Eligibility Criteria
Patients with chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease and so on.
You may qualify if:
- chronic liver diseases including: viral hepatitis, alcoholic liver disease, autoimmune liver disease.
- age: 15-65 years old.
You may not qualify if:
- pregnant women and women in lactation.
- other systems and organs disfunction
- space-occupying lesion were found in liver.
- concurrent infection with HIV and other immunodeficiency diseases.
- DIC and active bleeding were confirmed.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Infectious Diseases, 3rd Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510630, China
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 7, 2010
First Posted
December 8, 2010
Study Start
October 1, 2010
Last Updated
December 8, 2010
Record last verified: 2010-10